| Systematic (IUPAC) name | |
|---|---|
| (±)-(2R*,6S*)-2,6-dimethyl-4-{2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl}morpholine | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 78613-35-1 |
| ATC code | D01AE16 |
| PubChem | CID 54260 |
| ChemSpider | 49010 |
| UNII | AB0BHP2FH0 |
| KEGG | D02923 |
| ChEBI | CHEBI:599440 |
| ChEMBL | CHEMBL489411 |
| Chemical data | |
| Formula | C21H35N |
| Mol. mass | 317.509 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Amorolfine (or amorolfin), is a morpholine antifungal drug that inhibits D14 reductase and D7-D8 isomerase, which depletes ergosterol and causes ignosterol to accumulate in the fungal cytoplasmic cell membranes.
Marketed as Curanail, Loceryl, Locetar, and Odenil, Amorolfine is commonly available in the form of a nail lacquer, containing 5% Amorolfine as the active ingredient. It is not approved for the treatment of onychomycosis in the United States or Canada. It is probably the most effective topical solution for the treatment of toenail infections, although 'systemic treatments are more effective.[1] It is safe enough to be offered over the counter to the general public in Australia and the UK (recently re-classified to over the counter status) and is approved for the treatment of toenail fungus in other countries but requires a prescription.
Amorolfine 5% nail lacquer in once-weekly or twice-weekly applications has been shown in two studies to be between 60% and 71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment) were 38% and 46%. However, full experimental details of these trials were not available and since they were first reported in 1992 there have been no subsequent trials.[1]
|
||||||||||||||||||||||||||||||||||||||||||||||